Immunic, a late-stage biotech company, announced a virtual R&D day on September 9, 2026, focusing on its oral therapy vidofludimus calcium for relapsing multiple sclerosis (MS). The event will feature company executives and leading MS experts discussing the drug's potential to address neurodegenerative and inflammatory aspects of MS. Top-line data from Phase 3 ENSURE trials are expected by the end of 2026, which could advance treatment options beyond traditional anti-inflammatory drugs. Immunic also plans to start a Phase 3 trial for progressive MS later in 2026.
Nvidia has returned a record $26 billion to its shareholders after increasing its dividend by an extraordinary 2,400%. This massive payout highlights the company's strong financial position and commitment to rewarding investors. The significant divid...
Campbell's and Lululemon both report earnings on September 3, 2026, but Campbell's full fiscal year results and guidance reset carry more weight for retirement-focused investors than Lululemon's mid-year quarter. Campbell's defensive food business of...
cbdMD announced an agreement to acquire Twinlab's operating assets and brands, including Reserveage, Metabolife, and Alvita Tea, aiming to increase its revenue by about 40% to $30 million. This acquisition will diversify cbdMD's offerings beyond hemp...
Apollo Commercial Real Estate Finance, Inc. has scheduled a special shareholder meeting for September 29, 2026, to vote on a Plan of Complete Liquidation and Dissolution. If approved, shareholders can expect an initial cash distribution of $3.70 to $...
American Battery Technology (ABAT) maintains a Buy rating, though with less confidence due to new regulatory risks that overshadow its valuation safety margin. The company reported strong Q4 FY26 results with $8.2 million revenue (up 5.1% QoQ), $1.3 ...
